Creating A World Of Connection For People With Hearing And Balance Disorders. It began with a zoom call only with the hiring manager followed by a seminar that I delivered to a broad audience of Arrakis . The company's TRYST™ and PEARL-seq™ platforms identify new RNA targets and drug candidates to treat diseases unaddressed by today's medicines. Dr. Gilman is CEO of Arrakis and Chairman of the Board of Directors. It may not be complete. Colleen Cuffaro Board Member. CAMP4 Therapeutics Promotes Kelly Gold to Chief Financial Officer. Our best-in-class broadly neutralizing antibodies . Add company. The company was co-founded in 2015 by CEO Michael Gilman, a former Biogen executive who co-founded and led Padlock Therapeutics and Stromedix. Arrakis Therapeutics has added information to its read more company news. The company's TRYST™ and PEARL-seq™ platforms identify new RNA targets and drug candidates to treat diseases unaddressed by today's medicines. Project. Project. We use this novel approach to degrade therapeutically relevant protein targets, including those previously considered undruggable. Previously, Mike was Chief Executive Officer of Obsidian Therapeutics, a venture-funded company . CXOreach. The company's platform integrates leading-edge RNA bioinformatic and structural tools to produce a pipeline of rSMs to treat a range of disease including neurology, oncology and rare genetic diseases, enabling physicians to offer enhanced care. Our approach builds on the existing sophisticated drug discovery toolkit developed for . Useful Links. Relay Therapeutics® puts protein motion at the heart of drug discovery to dramatically expand therapeutic possibilities. [email protected] +41 (0) 61 638 23 50. Through a unique cancer treatment . Salaries posted anonymously by Kriya Therapeutics employees in North Carolina. Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Explore Our Pipeline. Arrakis is developing a proprietary pipeline of RNA-targeted small molecules focused on neurologic diseases . Arrakis Therapeutics, Inc. has 75 total employees across all of its locations and generates $9.45 million in sales (USD). Read More. Arrakis is on a path to bring powerful new RNA-targeted small molecule (rSM) therapies to millions of patients. BioXcel Therapeutics to Present at Three Upcoming Investor Conferences VIEW RELEASE. The other (weirdly) was our outside patent counsel. Dr. Petter is the founding CEO and current CSO of Arrakis Therapeutics. Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. BTAI. About us. LifeMine Therapeutics is pioneering a genomically-enabled drug discovery approach integrating advanced life science and computational technologies to elucidate human biology and create . Dramatic advances in human genetics . The intellectual property of Arrakis Therapeutics includes 4 registered patents primarily in the ' Organic Chemistry ' category, according to IPqwery. Apr 22 2022. Link to: Microbiome LBP Manufacturing. Arrakis is developing a proprietary pipeline of RNA-targeted . Infrastructure. [email protected]) being used 94.9% of the time. Arrakis is building a proprietary pipeline of RNA-targeted small . CXOreach is an online Free B2B Database & Business Intelligence website. Apply Now Job Salary Company Rating Description: Do you have the passion to join a group whose mission is to pioneer the discovery of a new class of medicines to treat diseases unaddressed by today's therapies? Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. We focus on delivering quality data for all regions such as United States, Asia, Europe, Middle East, India and Oceania startups, corporates, etc. Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to Identify Novel RNA Degrader Small Molecule Therapeutics JOIN THE EXPEDITION We are on a mission that takes fearlessness and resilience to pioneer new science, but we also make enjoying the journey as important as the destination. An experienced drug hunter, scientist, and life science executive, Dr. Petter's research has spanned different fields over the years, with a current focus on RNA at Arrakis. harnessing the potential of modern human genetics to treat disease. In addition, Mike currently serves on the Board of Directors of Novartis Venture Fund, Obsidian Therapeutics, and Scholar Rock and on the Scientific Advisory Board of FutuRx. Other common formats are first (ex. Arrakis Therapeutics Pharmaceutical Manufacturing Waltham, MA 6,601 followers Arrakis is on a path to bring powerful new RNA-targeted small molecule (rSM) therapies to millions of patients. . Read More. Join Our Team. Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. We're looking for high-performing individuals who are passionate about science and excited to work in a collaborative environment fueled by a rigorous and entrepreneurial culture. Pipeline. Kriya Therapeutics Salaries trends. [email protected] 617.858.0041. Chief Executive Officer. Learn how we are integrating artificial intelligence, chemistry, and biology to design . Expansion Therapeutics has significantly expanded on scientific founder Matt Disney's . Leading the next generation of engineered therapeutics. Russell Petter. Apr 23 2022. Skyhawk Therapeutics, Inc. 35 Gatehouse Drive Waltham, MA 02451 United States of America. Share Your Experiences Arrakis Therapeutics ★★★★★ Glassdoor has millions of jobs plus salary information, company reviews, and interview questions from people on the inside making it easy to find a job that's . Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetic. Read about our scientists' publications in Science, Nature Biotechnology, at ASGCT and more. PIPELINE. The Organization's Mission To re-architect drug discovery tools and methods to unlock previously inaccessible biology to create new medicines for millions of patients. At Arrakis, we dare to be extraordinary even when success isn't a guarantee. We are pioneers in cell and gene therapy. Expansion Therapeutics News: Expansion Therapeutics Raises $80 Million Series B. Department. Read All. Virtual interviews were blocked out for an entire morning. Waltham, MA $96K - $176K ( Glassdoor est.) Site Under Construction. Obsidian Therapeutics to Present Preclinical Data from cytoDRiVE® Platform at the American Associate of Cancer Research (AACR) Annual Meeting 2022. MARKET/SYMBOL. Apply Now Job Salary Company Rating Description: Do you have the passion to join a group whose mission is to pioneer the discovery of a new class of medicines to treat diseases unaddressed by today's therapies? I was in direct contact with HR and the hiring manager throughout the process. The company has developed a proprietary platform to identify new . Company profile page for Arrakis Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information 18 open jobs for Scientist nmr spectroscopy in Boston. Microbiome LBP Manufacturing. You can compare up to 12 companies. The company's platform integrates RNA bioinformatics, chemical biology tools, chemical and biological assays, and RNA-directed medicinal chemistry, enabling physicians to treat a range of diseases including neurology, oncology, and rare genetic diseases. Co-authors. [email protected]). Fueling a new field in drug development. Get Verified Emails for 68 Arrakis Therapeutics Employees Arcturus Therapeutics is a global late-stage clinical messenger RNA medicines and vaccines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. Home; My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. Gemini Therapeutics is a precision medicine company focused on the development of new therapies through a deeper understanding of disease. CAREERS. He joined Dynatrace as Chief Executive Officer in December 2021. Additionally, Arrakis Therapeutics has registered 4 trademarks with the most popular class being ' Pharmaceutical, veterinary and sanitary products ', according to IPqwery. TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell Therapy 25th Annual Meeting. Description. Their unique dual inhibition leads to creating . Arrakis is the capstone of my career. Arrakis Therapeutics is a developer of a drug discovery platform intended to target RNA. Arrakis Therapeutics 5.0 ★ Associate Director/Director, Business & Corporate Development Waltham, MA $93K - $177K ( Glassdoor est.) Arrakis Therapeutics is a biopharmaceutical company which offers a drug discovery platform intended to target RNA. Expertise in Key Program Areas. United States Stow. Arrakis Therapeutics. 18 May 2022. Apply Now Job Salary Company Rating Description: Do you have the passion to join a group whose mission is to pioneer the discovery of a new class of medicines to treat diseases unaddressed by today's therapies? Choose the right Crunchbase solution for you . Read More. Close. Jennifer Petter, Ph.D., is a Founder & Chief Innovation Officer of Arrakis Therapeutics. Average salary for Transcode Therapeutics Software Engineer in Munich: €107,388. Contact Information Website www.arrakistx.com Ownership Status Privately Held (backing) Division of Cancer Therapeutics and Division of Structural Biology; Yvette Newbatt. Prior to that, I was CSO at RaNA Therapeutics (now Translate Bio), initially focused on targeting the function of long noncoding RNA in epigenetic regulation, and later transitioning to an mRNA therapeutics company. Read All. Please remove a company to add a new one. Previously, Russ was Vice President of Drug Discovery at Avila Therapeutics and, upon the acquisition of Avila by Celgene in 2012, he became Celgene's Vice President of Chemistry, a position he held until leaving to found Arrakis in 2015. Associate Director/Director, Business & Corporate Development Waltham, MA. Paulina Hill Board Member Apr 2019. University of Oxford; Amir Faisal. Meet Our Team. Nader Amin. Arrakis Therapeutics has launched a read more company news. Search Scientist nmr spectroscopy jobs in Boston, MA with company ratings & salaries. We are sharply focused on dry AMD which is a disease comprised of numerous genetic variants. Our lead candidates are in the lead selection stage near the pre-clinical trial. Arrakis Therapeutics 5.0 ★ Scientist, Biophysics Waltham, MA $64K - $130K ( Glassdoor est.) NEWS. Dyno Therapeutics is applying AI technology to discover novel gene therapy vectors with transformative delivery properties for a vast landscape of human diseases. Our platforms enable us to identify therapeutic leads with exceptional speed and diversity. Additionally, Arrakis Therapeutics has registered 4 trademarks with the most popular class being ' Pharmaceutical, veterinary and sanitary products ', according to IPqwery. A unique therapeutic approach. We are genetic navigators, charting the complex maze of human genetics to create precision medicines to fight disease and help patients in need. Co-op, Medicinal Chemistry Waltham, MA. About Us; Our Science; Asset Management. Who We Are; Our Team; Dynamo Platform; Pipeline; Patients; Investors & Media; Careers; 399 Binney Street, 2nd Floor. At the time of our dinner, only two people outside his personal world knew. Arrakis Therapeutics is a biopharmaceutical company which offers a drug discovery platform intended to target RNA. Carisma Therapeutics is pioneering the development of CAR-Macrophages, a disruptive approach to immunotherapy. TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies. Our Company We believe in treatment equality and supporting those with unmet needs; Our Leadership Mycovia has taken great strides toward making a difference that matters; Our Mission Effecting positive change extends beyond the pursuit of therapeutic innovations; Our Responsibility The Mycovia Code of Conduct outlines specific practices and guidance designed to uphold Mycovia's mission and . April 8, 2022. Cyteir Therapeutics | 3,537 followers on LinkedIn. Current and former employees report that Arrakis Therapeutics provides the following benefits. Arrakis Therapeutics Pharmaceuticals. Drawing upon our extensive experience in developing therapeutics for chronic liver diseases and viral infections, we are building a pipeline of potentially best-in-class drug candidates. Helpful Report Work at Arrakis Therapeutics? Culture - Arrakis Therapeutics Defy the status quo, take the risks, lead with curiosity, believe in human kindness. We are leaping into the new possibilities of the RNA world, where every individual's contribution matters on our journey to help millions of patients. Beam Therapeutics is an equal opportunity employer and will not discriminate against any employee or applicant on the basis of age, color, disability, gender, national origin, race, religion, sexual orientation, veteran status, or any classification protected by federal, state, or local law. See. Contacts 49 About Arrakis Therapeutics has 5 current employee profiles, including CEO Michael Gilman. PLATFORM. Developer of a drug discovery platform designed to find new points of therapeutic intervention. Oldest First Easiest Most Difficult Interviews at Arrakis Therapeutics Experience Neutral 100% Getting an Interview Applied online 100% Difficulty 3.0 Average Hard Average Easy Interviews for Top Jobs at Arrakis Therapeutics Computational Biologist (1) See more interviews for top jobs Arrakis Therapeutics uses 2 email formats. Arrakis Therapeutics | 6,934 followers on LinkedIn. We're advancing a robust portfolio of therapeutic candidates bridging the innate and adaptive immune system. Company Description: Arrakis Therapeutics, Inc. is located in Waltham, MA, United States and is part of the Scientific Research and Development Services Industry. Based on 1 salaries posted anonymously by Transcode Therapeutics Software Engineer employees in Munich. Jennifer Petter Founder & CSO Executive Operations 1 email found View Katrine Bosley Chairman of the Board Cambridge, MA 02139. [email protected] (617) 370-8837. The most common Arrakis Therapeutics email format is first_initial last (ex. Rick McConnell has been a successful technology executive for 30 years, establishing a reputation for scaling multibillion-dollar companies in competitive growth markets. Skyhawk Therapeutics Europe GmbH Basel Technology Park Hochbergerstrasse 60C Basel 4057 Switzerland. Current Openings - Arrakis Therapeutics. Learn More About Us. Novel Therapeutics, Meaningful Connections. Life at Decibel. Learn About Our Science. VIEW ALL NEWS. These drug candidates target multiple clinically validated mechanisms of action and are designed to achieve high rates of functional cure for CHB and . Press Release. Our technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease. The Company develops an internal product pipeline of RNA-targeted small molecules focused on neurology, oncology, and rare genetic disorders. Top co-authors. BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights VIEW RELEASE. ABOUT. Prior to Dynatrace, he was President at Akamai Technologies and General Manager of . ABOUT US. Our approach. Our team embraces innovation and collaboration. Contact Us; Privacy Policy Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Company profile page for Arrakis Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information PRICE. 18 open jobs for Scientist nmr spectroscopy in Boston. Maze Therapeutics: translating genetic insights into therapeutic innovations. One was Heather Lounsbury, our VP of Ops and Russ's long-time partner-in-crime at Avila and Celgene prior to Arrakis. April 11, 2022. Learn More. We also believe that more precisely targeted therapeutics could better address the cause of a patient's disease. The intellectual property of Arrakis Therapeutics includes 4 registered patents primarily in the ' Organic Chemistry ' category, according to IPqwery. Pioneering The Development of Novel Therapeutics Targeting Stress Support Pathways. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based . 11.17. Later that week in the office, Russ shared with Heather and me a proposed timetable for when he . BioXcel Therapeutics, Inc. Jun 03, 2022 04:00 PM. Read about Dyno's cutting edge lab where high-throughput experiments power our search for . Start Your Free Trial . We are looking for talented individuals to join the Arrakis team in the following positions: Research Associate/Senior Research Associate, Biophysics Waltham, MA. Arrakis is building a proprietary pipeline of RNA-targeted small . Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis Therapeutics 5.0 ★ Associate Director/Principal Scientist, Machine Learning/A.I. Employee Benefit Reviews Showing 1-1 of 1 comments Mar 6, 2022 5.0 ★★★★★ Former Employee 401k and insurances are great at Arrakis. Arrakis Therapeutics has 4 board members and advisors, including Colleen Cuffaro. English (2 reviews) Other English (2 reviews) 5.0 ★★★★★ Former Employee, more than 3 years Awesome team Nov 1, 2021 - Scientist in Boston, MA Recommend CEO Approval Business Outlook Pros . Ribon is a clinical stage biopharmaceutical company pursuing the development of novel small molecules targeting stress support pathways in cancer and inflammation using our proprietary BEACON + (Blocking the Enzyme Activity Component of NAD +) platform. The company's TRYST™ and PEARL-seq™ platforms identify new RNA targets and drug candidates to treat diseases unaddressed by today's medicines. Read More. Creating advanced therapies is audacious. As a trusted CDMO, Arranta Bio helps ensure your success by providing process development, manufacturing expertise and bold solutions that take your program from the lab to the patient. Arrakis is developing a proprietary pipeline of RNA-targeted . May 05, 2022. Arrakis Therapeutics's top competitors include ROPHIBIO, Reglagene, Exicure and Cytura Therapeutics. Katrine Bosley Board Member 2019. Arrakis Therapeutics Pharmaceutical Manufacturing Waltham, MA Beam Therapeutics Biotechnology Research . It offers scientific platforms, such as TRYST, MARS, PEARL-Seq, to identify tractable RNA . Find high paying available jobs at Arrakis Therapeutics.For expert network information on Arrakis Therapeutics compensation and careers, use Ladders $100K + Club. Monte Rosa's MGDs are rationally designed drug-like small molecules that create complementary surfaces between two proteins. Company Description: Arrakis Therapeutics, Inc. is located in Waltham, MA, United States and is part of the Scientific Research and Development Services Industry. Small molecules, big difference. Search Scientist nmr spectroscopy jobs in Boston, MA with company ratings & salaries. | Arrakis has a simple but powerful vision: To extend small-molecule medicines into new realms of biology, unlocking that biology for medicine. Autobahn Therapeutics Announces Emerging Preclinical Data Demonstrating Ability of CNS-Delivered Thyromimetics to Promote . More. Adagio Therapeutics Inc. Our mission is to provide an effective long-term solution for the global coronavirus challenge. the maze approach. Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Stock Information. 1 salaries for 1 jobs at Kriya Therapeutics in North Carolina. Highly potent broadly neutralizing antibodies offer the best possibility to resolve the current COVID19 pandemic while also preparing for future outbreaks of related viruses.